Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04261881 · ClinicalTrials.gov registry record · NA
Nutraceutical Support of Fatigue Reduction, Improved Physical, Mental & Cognitive Function and Mitochondrial Function
A NA study, sponsored by Natural Immune Systems.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT04261881: Completed NA study, sponsored by Natural Immune Systems.
NCT04261881 is a NA study that has completed, run by Natural Immune Systems. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04261881, a NA study, has completed, sponsored by Natural Immune Systems.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose for this protocol is to perform an open-label human clinical pilot study on the effects of consumption of two nutraceutical blends in subjects with long-term unexplained fatigue interfering with daily living.
Primary Outcome
Piper Fatigue Scale - Change from baseline will be evaluated. Each question scores 0-10, 22 questions.
Interventions
- DIETARY_SUPPLEMENT ATP-Fuel
- DIETARY_SUPPLEMENT ATP-II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-03-27 |
| Est. Completion | 2020-04-08 |
| Phase | NA |
What the finished NCT04261881 record still lists
NCT04261881 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which ATP-Fuel is the first listed.
NCT04261881 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04261881 about?
NCT04261881 is a clinical study titled "Nutraceutical Support of Fatigue Reduction, Improved Physical, Mental & Cognitive Function and Mitochondrial Function". The purpose for this protocol is to perform an open-label human clinical pilot study on the effects of consumption of two nutraceutical blends in subjects with long-term unexplained fatigue interfering with daily living.
What is the current status of trial NCT04261881?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2018-03-27. Estimated completion is 2020-04-08.
What interventions are being tested in trial NCT04261881?
The interventions under investigation include: ATP-Fuel (DIETARY_SUPPLEMENT), ATP-II (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04261881?
This trial is sponsored by Natural Immune Systems, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04261881's enrollment target sits among peer trials
36 1541st of 2000 higher than 437 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI